Centessa IPO Presentation Deck

ApcinteX Developing SerpinPC, a Phase 2 stage specific inhibitor of activated protein C (APC) for treatment of hemophilia A & B (HA, HB) Mission Develop a monthly subcutaneous therapeutic for hemophilia A & B patients that significantly reduces bleeding rates and avoids excessive blood coagulation via inhibition of activated protein C De-risking data Coinheritance of Factor V Leiden mutation (reduced APC) with hemophilia associated with mild bleeding phenotype Single injection of SerpinPC in 12 subjects with severe hemophilia resulted in marked reduction in all bleeds, including in joint and muscle, over 8-week period Apcintex Lack of D-dimer elevation in animal species, HVs, and hemophilia patients Market opportunity Estimated global prevalence of HA and HB ~400,000 individuals ~$11 billion global hemophilia market CENTESSA 17

View entire presentation